← Back to Search

Unknown

Part 1, ABBV-903 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to day 66

Summary

This trial is testing a new drug called ABBV-903 to see if it is safe and well-tolerated by healthy adults. Researchers want to know how the drug behaves in the body when taken in different doses.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to day 66
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to day 66 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Apparent Terminal Phase Elimination Constant (β)
Area Under the Plasma Concentration-time Curve (AUC)
Area Under the Plasma Concentration-time Curve from Time 0 Until Infinity (AUCinf)
+5 more

Trial Design

6Treatment groups
Experimental Treatment
Group I: Part 3, Sequence 2Experimental Treatment2 Interventions
Participants in Part 3 will follow Sequence 2.
Group II: Part 3, Sequence 1Experimental Treatment2 Interventions
Participants in Part 3 will follow Sequence 1.
Group III: Part 2, PlaceboExperimental Treatment1 Intervention
Participants will receive multiple ascending doses of placebo in Part 2.
Group IV: Part 2, ABBV-903Experimental Treatment1 Intervention
Participants will receive multiple ascending doses of ABBV-903 in Part 2.
Group V: Part 1, PlaceboExperimental Treatment1 Intervention
Participants will receive a single ascending dose of placebo in Part 1.
Group VI: Part 1, ABBV-903Experimental Treatment1 Intervention
Participants will receive a single ascending dose of ABBV-903 in Part 1.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo for ABBV-903
2023
Completed Phase 1
~110
ABBV-903
2023
Completed Phase 1
~140
Itraconazole
2017
Completed Phase 2
~830

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

AbbVieLead Sponsor
1,023 Previous Clinical Trials
520,210 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
444 Previous Clinical Trials
160,696 Total Patients Enrolled

Media Library

ABBV-903 (Unknown) Clinical Trial Eligibility Overview. Trial Name: NCT05691699 — Phase 1
Healthy Subjects Research Study Groups: Part 2, Placebo, Part 1, ABBV-903, Part 2, ABBV-903, Part 3, Sequence 1, Part 1, Placebo, Part 3, Sequence 2
Healthy Subjects Clinical Trial 2023: ABBV-903 Highlights & Side Effects. Trial Name: NCT05691699 — Phase 1
ABBV-903 (Unknown) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05691699 — Phase 1
~37 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top